A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Golimumab (Primary) ; Infliximab
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms PURSUIT 2
- Sponsors Janssen Research & Development
- 31 Oct 2018 Status changed from not yet recruiting to recruiting.
- 08 Oct 2018 Planned initiation date changed from 21 Sep 2018 to 11 Oct 2018.
- 30 Jul 2018 New trial record